Retrospective observational study shows stable growth hormone levels in acromegaly patients, suggesting monitoring IGF-1 may suffice.
Most patients achieved a mid- to long-term disease-controlled state without additional treatment. Given the potential risk of GH deficiency from further treatment, it may be reasonable to consider patients clinically controlled as long as IGF-1 levels remain normalized, with careful long-term monitoring recommended.
No takes yet. Share an insight, caveat, or question.
Ishida et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: